A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2006
12/07/2006	US20060276471 Useful in therapy and treatment of diseases associated with a disregulated protein kinase activity like cancer; Aurora kinases
12/07/2006	US20060276444 Porphyrin-polyamine conjugates for cancer therapy
12/07/2006	US20060276433 Hydrazone derivative
12/07/2006	US20060276432 Lipid-regulating agent and use thereof
12/07/2006	US20060276427 Regulation of endogenous gene expression in cells using zinc finger proteins
12/07/2006	US20060276424 Compositions and Methods for Treatment of Prostate and Other Cancers
12/07/2006	US20060276399 Peptide antagonists of zonulin and methods for use of the same
12/07/2006	US20060276396 Stimulating insulin synthesis and release, enhancing adipose, muscle or liver tissue sensitivity towards insulin uptake, stimulating glucose uptake, slowing digestive process, or blocking the secretion of glucagon; glucagon-like protein
12/07/2006	US20060276386 Use of substances inhibiting the association of said protein with ubiquitin c-terminal hydrolase for altering cellular responses to tgf-beta or bmp
12/07/2006	US20060276339 Methods and compositions for increasing the efficacy of biologically-active ingredients
12/07/2006	US20060275791 Biological control of nanoparticle nucleation, shape and crystal phase
12/07/2006	US20060275755 Novel nucleic acids and polypeptides related to a guanine exchange factor of rho gtpase
12/07/2006	US20060275359 Palliative effects of morinda citrifolia oil and juice
12/07/2006	US20060275328 Instrument for inducing cytokine and method of inducing cytokine
12/07/2006	US20060275305 HERCEPTIN adjuvant therapy
12/07/2006	US20060275304 Novel tumor antigen useful in diagnosis and therapy of prostate and colon cancer
12/07/2006	US20060275302 a novel DNA, a carcinoma-associated gene comprising the DNA, a recombinant protein encoded by the DNA, an antibody binding to the protein, an anti-carcinoma agent comprising the antibody, a low-molecular-weight compound binding to the protein, a screening system
12/07/2006	US20060275301 Cell death-inducing agent
12/07/2006	US20060275299 Use of protein tyrosine phosphatase inhibitors for prevention and/or treatment of cancer
12/07/2006	US20060275287 Scroll compressor
12/07/2006	US20060275284 Combination therapy for treatment of autoimmune diseases using b-cell depleting/immunoregulatory antibody combination
12/07/2006	US20060275268 Compositions for activating the infiltration activity of dendritic cells, and immunopotentiating agents
12/07/2006	US20060275258 Interferon-alpha induced gene
12/07/2006	US20060275253 Beta hydroxy short to medium chain fatty acid polymer
12/07/2006	US20060275251 Polymer complexes of glucuronoglucanes
12/07/2006	US20060275213 Tumor targeting agents and uses thereof
12/07/2006	US20060275212 Treatment and diagnosis of cancer
12/07/2006	US20060275209 Methods of [11c]-radiolabelling phenothiazine and phenothiazine-like compounds
12/07/2006	DE102005024836A1 Composition for treatment and prevention of bone tumors and metastases to bone, comprises microorganisms that carry a gene for abnormal bone sialoprotein, inducing an immune response
12/07/2006	CA2610702A1 Targeting cells with altered microrna expression
12/07/2006	CA2610661A1 Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
12/07/2006	CA2610491A1 Bicyclic derivatives for the treatment of abnormal cell growth
12/07/2006	CA2610234A1 Antibodies directed to cd20 and uses thereof
12/07/2006	CA2609939A1 Fk 228 derivates as hdac inhibitors
12/07/2006	CA2609221A1 A peptide ligand to impair cancer cell migration
12/07/2006	CA2609032A1 Method for producing a nucleic-acid-containing complex preparation
12/07/2006	CA2608709A1 Treatment of liver diseases in which iron plays a role in pathogenesis
12/06/2006	EP1728865A1 Treatment of cervical cancer
12/06/2006	EP1728863A2 C-class oligonucleotide analogs with enhanced immunostimulatory potency
12/06/2006	EP1728802A2 ErbB3 antibodies
12/06/2006	EP1728801A1 Subtype of humanized antibody against interleukin-6 receptor
12/06/2006	EP1728793A1 9-substituted 8-oxoadenine compound
12/06/2006	EP1728792A1 8-oxoadenine compound
12/06/2006	EP1728790A1 Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases
12/06/2006	EP1728789A1 Antibiotic fki-1778 and process for producing the same
12/06/2006	EP1728518A1 Method of diagnosing monitoring, staging, imaging and treating gynecologic cancers and testicular cancer
12/06/2006	EP1728517A2 Methods for treating mammary gland disorders
12/06/2006	EP1728510A2 Treating cancer by increasing intracellular malonyl coA levels
12/06/2006	EP1728504A1 Emulsion stabilizer
12/06/2006	EP1727822A1 Novel compounds for modulating cell proliferation
12/06/2006	EP1727820A2 Amine derivatives
12/06/2006	EP1727819A1 Novel dichloro-phenyl-pyrido¬2,3-d\|pyrimidine derivatives, their manufacture and use as pharmaceutical agents
12/06/2006	EP1727817A1 Azabicyclooctan-3-one derivatives and use thereof
12/06/2006	EP1727802A1 Substituted quinoline compounds for use as selective estrogen receptor modulator
12/06/2006	EP1727566A2 Conjugated psychotropic drugs and uses thereof
12/06/2006	EP1727558A1 Use of dmbt1 for capturing sulphate and phosphate group exposing agents
12/06/2006	EP1727555A1 Production of hop extracts having oestrogenic and antiproliferative bioactivity
12/06/2006	EP1727548A2 Use of carboxypeptidase g for combating antifolate toxicity
12/06/2006	EP1727546A2 Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad
12/06/2006	EP1727537A2 Use of beta-lapachone for treating or preventing cancer
12/06/2006	EP1727536A1 Beta-lapachone and s-phase drug combinations for cancer treatment
12/06/2006	EP1727534A2 Hydroxymethylbutyrate compositions and uses thereof
12/06/2006	EP1727532A2 Chemically stable compositions of 4-hydroxy tamoxifen
12/06/2006	EP1727528A2 Inhibition of mixed lineage kinases and uses therefor
12/06/2006	EP1682571A4 A bidentate motif and methods of use
12/06/2006	EP1682570A4 A binding motif and methods of regulating cell function
12/06/2006	EP1631146A4 Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
12/06/2006	EP1456212B1 6-aminomorphinane derivatives, method for the production and use thereof
12/06/2006	EP1368319B1 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use as adenosine receptor-selective ligands
12/06/2006	EP1318977B1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
12/06/2006	EP1313459B1 Polycyclic dianthraquinones as anti-cancer and anti-angiogenic agents
12/06/2006	EP1165078B1 Methods of inducing cancer cell death and tumor regression
12/06/2006	EP1137411B1 Palladium-substituted bacteriochlorophyll derivatives and use thereof
12/06/2006	EP1078001B1 Il-6 antagonist peptides
12/06/2006	EP0983346B1 Short peptides which selectively modulate the activity of serine/threonine kinases
12/06/2006	EP0948334B1 Method of treating prostatic diseases using active vitamin d analogues
12/06/2006	EP0915871B1 Substituted bisindolylmaleimides for the inhibition of cell proliferation
12/06/2006	EP0837934B1 Human vascular endothelial growth factor 2
12/06/2006	EP0812333B1 Bispecific antibody effective to treat b-cell lymphoma and cell line
12/06/2006	EP0740701B1 Mammalian monocyte chemoattractant protein receptors
12/06/2006	CN1875023A Use of thienopyrimidines
12/06/2006	CN1875022A Tocopherol-modified therapeutic drug compounds
12/06/2006	CN1874790A Therapeutic agent for mesothelioma
12/06/2006	CN1874783A Agent against malignant neuroglia and agent against malignant neuroglia for animals
12/06/2006	CN1874781A Compositions of botanical extracts for cancer therapy
12/06/2006	CN1874780A Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemot
12/06/2006	CN1874776A 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
12/06/2006	CN1873020A Diagnosing suppressor gene RhoGDI2 of tumour transfe, and therapeutic methods
12/06/2006	CN1873013A Recombinant adenoviral vector and methods of use
12/06/2006	CN1872997A New technique for culturing stem cells (carrying therapy gene) of human's xenogenic stromata in large-scale
12/06/2006	CN1872879A Anagonism active polypeptide of CXCR4 acceptor from inflammation protein of virus macrophage
12/06/2006	CN1872877A Idiosyncratic antigen protein, and antigen peptide of liver cancer orchis pellet
12/06/2006	CN1872857A Reverse-turn mimetics and method relating thereto
12/06/2006	CN1872856A Reverse-turn mimetics and method relating thereto
12/06/2006	CN1872851A Compound of alpha ¿C methylene ¿C gamma ¿C butyrolactone, preparation method, and method
12/06/2006	CN1872850A N－苯基－2－嘧啶胺衍生物 N- phenyl-2-pyrimidine-amine derivative
12/06/2006	CN1872847A Compound of saturated bicyclic ring in cyclohexanone class, preparation method and application
12/06/2006	CN1872838A Compound of monocyclic polysubstitution saturated cyclohexanones, prepartion method and usage
12/06/2006	CN1872834A Method for preparing compound of fluoro aromatic hydrocarbon
12/06/2006	CN1872828A Monocyclic polysubstitution cyclohexenol, and compound of ketones, and preparation method, and usage

1 ... 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 ... 2211